These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 31681269)

  • 1. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
    Sun H; Sun C
    Front Immunol; 2019; 10():2354. PubMed ID: 31681269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
    Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
    J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The "immune checkpoints", how does it work].
    Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
    Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
    Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
    Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
    Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
    Front Immunol; 2019; 10():1242. PubMed ID: 31214193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
    Skafi N; Fayyad-Kazan M; Badran B
    Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
    Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
    Front Immunol; 2019; 10():491. PubMed ID: 30936880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of NK Cell Activation by Immune Checkpoint Molecules.
    Beldi-Ferchiou A; Caillat-Zucman S
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29023417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-Checkpoint Blockade Therapy in Lymphoma.
    Kuzume A; Chi S; Yamauchi N; Minami Y
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.
    Liu Y; Cheng Y; Xu Y; Wang Z; Du X; Li C; Peng J; Gao L; Liang X; Ma C
    Oncogene; 2017 Nov; 36(44):6143-6153. PubMed ID: 28692048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
    Azoury SC; Straughan DM; Shukla V
    Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
    Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
    Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing NK Cells for Cancer Treatment.
    Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
    Front Immunol; 2019; 10():2836. PubMed ID: 31867006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.